Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a global ...

Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...

Embecta, a company that develops diabetes management solutions, is moving into the auto-injection market with its latest planned acquisition. The Becton Dickinson & CO spinoff reported it would ...

Diabetes drugmaker Xeris Pharmaceuticals made a $75 million bet last summer when it went public to back an FDA submission for its shelf-stable glucagon injector pen. Now, more than a year later, Xeris ...

Zegalogue will be available in both an auto injector and a prefilled syringe for the treatment of severe hypoglycemia in patients with diabetes age 6 or older Approval based on results from three ...

CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...